Five Clinical Presentations Highlight Shionogi Pharma, Inc.'s PSD502, an Investigational Treatment for Primary Premature Ejaculation

Wednesday, May 26, 2010 General News J E 4
Data to be Presented at AUA 2010 Annual Meeting


Presentation Title

Lead Author

June 01, 2010

8:40 – 8:50AM PT

An integrated summary of the results of two pivotal phase III studies of PSD502 for premature ejaculation (PE)

Ira D. Sharlip, MD, University of California at San Francisco, San Francisco, CA

June 01, 2010

8:50 – 9:00AM PT

Does time matter? Determination of the relationship between increasing ejaculatory latency in men with premature ejaculation and the domains of the index of premature ejaculation (IPE)

Stanley E. Althof, PhD, University of Miami Miller School of Medicine, West Palm Beach, FL

June 01, 2010

11:10 – 11:20AM PT

PSD502: A second phase III, randomized, double-blind, placebo-controlled study in premature ejaculation (PE) patients in the US and Europe

Culley C. Carson, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC

June 01, 2010

11:20 – 11:30AM PT

PSD502 appears to be effective in both circumcised and un-circumcised men with premature ejaculation (PE)

Wayne Hellstrom, MD, FACS, Tulane University School of Medicine, New Orleans, LA

June 01, 2010

1:50 – 2:00PM PT

Efficacy is maintained and may be enhanced using long-term (1yr) administration of PSD502 for premature ejaculation (PE)

Michael A. Perelman, PhD, New York Presbyterian Hospital, New York, NY



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Select Medical Holdings Corporation Announces Appo...
Louisiana's Revamped Medicaid Program Will Likely ...